Publications by authors named "Michael Tanaka"

Claim this Profile
C
Coronavirus disease 2019 and cardiovascular system: A narrative review.
Felix Kwenandar, Karunia Valeriani Japar, Vika Damay, Timotius Ivan Hariyanto, Michael Tanaka

Int J Cardiol Heart Vasc· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy.
Thomas J Semrad, Edward J Kim, Michael S Tanaka, Jacob Sands, Chris Roberts

Cancer Treat Res Commun· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Progression-Free Survival in a Patient with Locally Advanced, Unresectable Pancreatic Adenocarcinoma.
Brandon A Dyer, Leonel A Kahn, Mahan Matin, Richard J Bold, Michael I Tanaka

Cureus· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.
Thomas Semrad, Afsaneh Barzi, Heinz-Josef Lenz, Irene M Hutchins, Edward J Kim, Michael Tanaka

Int J Clin Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.
Cheryl Ho, Randeep Sangha, Laurel Beckett, Michael Tanaka, Derick H Lau

Invest New Drugs· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Ramesh K Ramanathan, Chandra P Belani, Deepti A Singh, Michael Tanaka, Heinz-Josef Lenz

Cancer Chemother Pharmacol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-based phase I trial of irinotecan and epirubicin.
Derick Lau, Jewel Johl, Minh Huynh, Angela Davies, Michael Tanaka

Am J Clin Oncol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Charles D Blanke, Cathryn Rankin, George D Demetri, Christopher W Ryan, Margaret von Mehren, Michael Tanaka

J Clin Oncol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Angela M Davies, Cheryl Ho, Alex S Metzger, Laurel A Beckett, Scott Christensen, Michael Tanaka

J Thorac Oncol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer.
Henry Wang, Janice Ryu, David Gandara, Richard J Bold, Shiro Urayama, Michael Tanaka

J Thorac Oncol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
Stephen R Smalley, Jacqueline K Benedetti, Stephen K Williamson, John M Robertson, Norman C Estes, Michael S Tanaka

J Clin Oncol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.
Robert P Whitehead, Sheryl McCoy, John S Macdonald, Saul E Rivkin, Marcus A Neubauer, Michael S Tanaka

Invest New Drugs· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
Cynthia L Martel, Yueju Li, Laurel Beckett, Helen Chew, Scott Christensen, Michael Tanaka

Cancer J· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-based maximum tolerated dose of irinotecan and carboplatin.
Carolyn A Wild, Stephen E Wang, David R Gandara, Primo N Lara, Frederick J Meyers, Michael Tanaka

Oncology (Williston Park)· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Nelson Lim, Primo N Lara, Derick H M Lau, Martin J Edelman, Michael Tanaka

Cancer Invest· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Premedication strategy for weekly paclitaxel.
Justin Quock, Gilland Dea, Michael Tanaka, David Gandara, Primo Lara

Cancer Invest· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis